At a glance
ClinicalIndex Comparison RecordN/ACompleted· 57 enrolled
Drug / intervention
The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project With Boston Scientific's Innova Drug Eluting Stent
In Brief
A clinical study evaluating The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA) for Atherosclerosis of Native Arteries of the Extremities. Completed, enrolled 57 participants across 13 sites in 5 countries.
Detailed Summary
To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Belgium, Germany, New Zealand
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartAug 2013
Primary CompletionDec 2014
Study CompletionFeb 2017
TodayJul 2026
First PostedMar 29, 2013
Enrollment StartAug 23, 2013
Primary CompletionDec 1, 2014
Study CompletionFeb 20, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.3 years ago
Interventions
The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)device
Drug-eluting SFA self-expanding stent